Functional Genomic Landscape of Acute Myeloid Leukaemia

The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity. Our data reveal mutational events that have not previously been detected in AML. We show that the response to drugs is associated with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA sequencing also revealed gene expression signatures, which predict a role for specific gene networks in the drug response. Collectively, we have generated a dataset-accessible through the Beat AML data viewer (Vizome)-that can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of AML.

Citing Articles

Integrated multiomics analysis and machine learning refine neutrophil extracellular trap-related molecular subtypes and prognostic models for acute myeloid leukemia.

Zhong F, Yao F, Wang Z, Liu J, Huang B, Wang X Front Immunol. 2025; 16:1558496.

PMID: 40066454 PMC: 11891243. DOI: 10.3389/fimmu.2025.1558496.

Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells.

Myeong J, Lee M, Lee B, Kim J, Nam Y, Choi Y Nat Commun. 2025; 16(1):2327.

PMID: 40057497 PMC: 11890575. DOI: 10.1038/s41467-025-57323-6.

Hypomethylation of isoform A correlates with transcriptional expression and is associated with poor survival in acute myeloid leukemia.

Wu D, Qiu H, Xu J, Lin J, Qian J Front Immunol. 2025; 16:1490330.

PMID: 40034691 PMC: 11873079. DOI: 10.3389/fimmu.2025.1490330.

Potential value of immunogenic cell death related-genes in refining European leukemiaNet guidelines classification and predicting the immune infiltration landscape in acute myeloid leukemia.

Jiao C, Ma X, Cui J, Su B, Xu F, Chen E Cancer Cell Int. 2025; 25(1):52.

PMID: 39966805 PMC: 11837611. DOI: 10.1186/s12935-025-03670-9.

Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia.

Bao X, Chen Y, Chang J, Du J, Yang C, Wu Y BMC Cancer. 2025; 25(1):273.

PMID: 39955536 PMC: 11830216. DOI: 10.1186/s12885-025-13658-3.

References

Huntley M, Larson J, Chaivorapol C, Becker G, Lawrence M, Hackney J . ReportingTools: an automated result processing and presentation toolkit for high-throughput genomic analyses. Bioinformatics. 2013; 29(24):3220-1. PMC: 5994940. DOI: 10.1093/bioinformatics/btt551. View

. The International HapMap Project. Nature. 2003; 426(6968):789-96. DOI: 10.1038/nature02168. View

Falini B, Nicoletti I, Martelli M, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2006; 109(3):874-85. DOI: 10.1182/blood-2006-07-012252. View

Kurtz S, Eide C, Kaempf A, Khanna V, Savage S, Rofelty A . Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017; 114(36):E7554-E7563. PMC: 5594650. DOI: 10.1073/pnas.1703094114. View

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil C, Mehta S . SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014; 25(2):226-42. PMC: 4106711. DOI: 10.1016/j.ccr.2014.01.022. View

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

10.

Parsana P, Ruberman C, Jaffe A, Schatz M, Battle A, Leek J . Addressing confounding artifacts in reconstruction of gene co-expression networks. Genome Biol. 2019; 20(1):94. PMC: 6521369. DOI: 10.1186/s13059-019-1700-9. View

11.

Zheng X, Levine D, Shen J, Gogarten S, Laurie C, Weir B . A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics. 2012; 28(24):3326-8. PMC: 3519454. DOI: 10.1093/bioinformatics/bts606. View

12.

Canisius S, Martens J, Wessels L . A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 2016; 17(1):261. PMC: 5162102. DOI: 10.1186/s13059-016-1114-x. View

13.

Daigle S, Olhava E, Therkelsen C, Majer C, Sneeringer C, Song J . Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011; 20(1):53-65. PMC: 4046888. DOI: 10.1016/j.ccr.2011.06.009. View

14.

Langfelder P, Luo R, Oldham M, Horvath S . Is my network module preserved and reproducible?. PLoS Comput Biol. 2011; 7(1):e1001057. PMC: 3024255. DOI: 10.1371/journal.pcbi.1001057. View

15.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

16.

Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

17.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O . Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147-52. DOI: 10.1038/leu.2011.71. View

18.

DiNardo C, Pratz K, Letai A, Jonas B, Wei A, Thirman M . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(2):216-228. DOI: 10.1016/S1470-2045(18)30010-X. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

Knapper S, Burnett A, Littlewood T, Kell W, Agrawal S, Chopra R . A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006; 108(10):3262-70. DOI: 10.1182/blood-2006-04-015560. View